Announcements Trials
Browse Landscape

Status

Completed 1050Recruiting 362Terminated 276Unknown 264Active not recruiting 152Withdrawn 101Not yet recruiting 79Suspended 13Enrolling by invitation 13Available 2No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

CNS 1Breast 1

Conditions

Glioblastoma 11Glioma 7Neuroblastoma 6Pheochromocytoma 3Paraganglioma 2Melanoma 2Diffuse Intrinsic Pontine Glioma 2Wilms Tumor 1Thyroid cancer, medullary 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Retinoblastoma 1Pinealoma 1Oligodendroglioma 1Neurofibromatosis 2 1Neuroectodermal Tumors, Primitive 1Neoplasms by Site 1Neoplasms 1Meningeal Neoplasms 1Meningeal Carcinomatosis 1Medulloblastoma 1Insulinoma 1Hepatoblastoma 1Gastrointestinal Stromal Tumors 1Dysbiosis 1Disease Progression 1Disease 1Carcinoid Tumor 1Breast Neoplasms 1

Interventions

tucatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
No longer available × Brain Neoplasms × CNS × Clear all
NCT03424473 2020-02-25

Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer

Seagen Inc.

No longer available
BreastCNS

Brain Neoplasms, Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site

Data powered by HemOnc (CC BY 4.0) Colophon âš¡